• Earlier this week, Exelixis drew attention after a report said a rival’s triple‑drug kidney cancer regimen failed in a Dow Jones pharma update, highlighting Exelixis as a key competitor in this treatment area.
• This setback for a competing approach subtly improves the perceived competitive position of Exelixis’s kidney cancer franchise at a time when oncology differentiation is critical.
• We’ll now explore how a rival’s failed kidney cancer regimen may influence Exelixis’s existing oncology narrative and future prospects.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

Exelixis Investment Narrative Recap

To own Exelixis, you have to believe its oncology portfolio can stay relevant as treatment standards evolve, while it gradually reduces its reliance on CABOMETYX. The setback for a rival’s triple‑drug kidney cancer regimen modestly eases competitive pressure in renal cell carcinoma, but it does not fundamentally change the key near term catalyst around pipeline progress or the central risk of future cabozantinib concentration and potential erosion.

The most relevant upcoming event is Exelixis’ first quarter 2026 earnings release and business update on May 5. With the stock recently buoyed by news on a competitor’s failed kidney cancer approach, that call may give investors a clearer view on how management frames competitive positioning, oncology trial priorities and capital allocation, all of which tie directly into the company’s catalyst path and its dependence on a single core franchise.

But beneath the improved competitive optics in kidney cancer, investors should be aware of the longer term vulnerability around cabozantinib’s eventual patent expiry and...

Exelixis' narrative projects $3.3 billion revenue and $1.2 billion earnings by 2029. This requires 12.0% yearly revenue growth and an earnings increase of about $417 million from $782.6 million today.

Uncover how Exelixis' forecasts yield a $46.83 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest analysts were already assuming Exelixis earnings could fall toward about US$590 million by 2029, so when you weigh this new kidney cancer setback for a rival against those more cautious views on competition and margins, it is a useful reminder that reasonable people can see very different futures for the same company and you should compare several perspectives before deciding what you believe.

Explore 10 other fair value estimates on Exelixis - why the stock might be worth over 4x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Exelixis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Exelixis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Exelixis' overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• Uncover the next big thing with 26 elite penny stocks that balance risk and reward.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.